The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
The FDA will rule on a low dose of zongertinib in the summer.
A triplet did worse than control in first-line kidney cancer.
Meanwhile, Tango tries again in PRMT5.
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Halda, Accent and Vividion take more projects into phase 1.
